Objectives: To investigate the efficacy of drug-coated balloon (DCB) for calcified coronary lesions.
2 | METHODS
| Patients
Consecutive patients successfully treated with DCB for de novo stable coronary lesions between June 2014 and September 2016 at Matsunami General Hospital (Kasamatsu, Japan) were retrospectively enrolled. Patients with acute coronary syndrome were excluded. They were divided into two groups according to the severity of lesion calcification at initial coronary angiography. All patients with moderately or severely calcified lesions were assigned to the calcified group, whereas other patients were assigned to the non-calcified group. Severely calcified lesions were defined as radiopacities noted without cardiac motion before contrast injection that generally involved both sides of the vessel wall. Moderately calcified lesions were defined as radiopacities noted only during the cardiac cycle before contrast injection. 6 All PCI cases were aided by intravascular ultrasound or optical coherence tomography for intravascular imaging during the procedure. Before DCB treatment, lesion preparation was routinely performed using Lacrosse NSE (Goodman Co., Ltd., Nagoya, Japan), a scoring balloon with three longitudinal synthetic resin elements on its surface. The balloon size was 90% of the vessel diameter, as evaluated by intravascular imaging with an inflation pressure of 6-14 atm. If required, rotational atherectomy using the Rotablator (Boston Scientific, Natick, MA) was performed at the discretion of the treating physician. The burr/vessel ratio was 0.5-0.7, and the rotational speed of the burr was 175 000 rpm (195 000 rpm only for a 1.25-mm burr). After an interval of at least 15 min after successful lesion preparation, DCB treatment was performed only in cases without flow-limiting dissection or severe elastic recoil, as evaluated by both angiography and intravascular imaging. The DCB, paclitaxel-coated balloon (SeQuent Please; B Braun, Melsungen, Germany), was used according to the German consensus statement. 7 All patients received aspirin 100 mg before the procedure and were recommended to continue it indefinitely, and clopidogrel 75 mg daily following a 300-mg loading dose or prasugrel 3.75 mg daily following a 20-mg loading dose was commenced before the procedure and continued for at least 3 months. 
| Statistical analyses
Variables with a normal distribution are presented as mean values ± standard deviation (SD), and asymmetrically distributed data are expressed as median and interquartile range (IQR). Differences between the groups for continuous variables were evaluated using
Mann-Whitney U test or Student's t-test and by using the chi-square test for categorical variables. The Kaplan-Meier method was used to estimate the event-free survival in the two groups, and the log-rank test was used to compare the differences between the groups. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated for each endpoint using a Cox proportional hazards model. A P value of <0.05 was considered statistically significant. To reduce the selection bias between the two groups, propensity score was calculated by logistic analysis from the baseline variables with P < 0.05 by univariate analysis between the two groups, and was incorporated into the Cox model as a covariate. The score was also incorporated into the analysis of covariance (ANCOVA) as a covariate in analyzing the difference of late lumen loss between the two groups. Statistical analyses were performed using JMP version 9.0 (SAS Institute, Cary, NC).
The study protocol was approved by the institutional ethics committee and conducted in accordance with the Declaration of Helsinki.
3 | RESULTS
| Baseline characteristics
A total of 81 patients (96 lesions) were included in the analysis: 46 patients (55 lesions) in the calcified group and 35 patients (41 lesions)
in the non-calcified group.
In the calcified group, patients were older and were more frequently on hemodialysis, compared to those in the non-calcified group (72 ± 7 vs 67 ± 10 years, P = 0.031 and 30.4% vs 8.8%, P = 0.015, respectively) (Table 1) ; the rates of type B2/C lesions and rotational atherectomy were significantly higher in the calcified group than in the non-calcified group (80.0% vs 39.0%, P < 0.0001 and 81.8% vs 14.6%, P < 0.0001, respectively) ( 
| Angiographic follow-up data
Complete follow-up angiography was performed for 30 patients 
| Clinical follow-up data
During the follow-up period (median, 12.2 months), 6 TLR (4 in the calcified group and 2 in the non-calcified group), and 3 non-cardiac (Figure 1 and Table 4 ). The survival rates for MACE were also similar (88.8% vs 88.5% at 12 months, and 81.4% vs 88.5% at 24 months, respectively, HR 1.48, 95%CI 0.39-7.02, P = 0.57) ( Figure 2 and Table 4 ). The HRs of calcified lesions, adjusted by the propensity score, were 0.75 (95%CI 0.05-11.5, P = 0.85) for TLR and 0.39 (95%CI 0.05-3.91, P = 0.42) for MACE (Table 4) .
| DISCUSSION
The major finding of the present study is that clinical outcomes after High frequency of rotational atherectomy (more than 80%) was one of the greatest procedural characteristics in the calcified group. In previous studies, bail-out stenting after DCB treatment was required in 6-27% of the patients because of major dissection or elastic recoil, 5, 14, 15 while a recent report presented that most lesions treated with paclitaxel-eluting balloon and left with non-flow-limiting dissection sealed and did not show significant neointimal hyperplasia in the late phase. 16 Provided that outcomes after DCB with provisional stenting had limited efficacy, 5 particularly in small vessels, 15 the requirement of stenting should be decided before application of drugs by DCB. Early elastic recoil was known as a phenomenon that often occurs within 15 min after angioplasty. 17, 18 In the present study, to avoid additional stenting after DCB treatment, a time interval more than 15 min was allowed after successful lesion preparation, and stentless strategy was relinquished before use of DCB in cases of flowlimiting dissection or severe elastic recoil. As a result, there was no crossover to additional stenting after DCB treatment in the present study.
| Limitations
The present study has some limitations. First, the number of patients was small because they were recruited from a single institution, and the rate of follow-up angiography was relatively low in the calcified group. Second, this study was conducted as a non-randomized, retrospective record review, and the baseline characteristics were different between the two groups. The assignment of strategies was at the discretion of the treating physician, and differences in individual practice, such as the use of RA could have influenced the outcomes.
Although propensity score was used in the analyses, the possibility of unobserved confounders can never be excluded. Third, the investigated lesions included many small vessels, and the results might not apply to all de novo PCI cases.
| CONCLUSION
Calcified coronary lesions might dilute the effect of DCB. However, clinical outcomes in the calcified group were similar to those in the non-calcified group.
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